Showing 21-30 of 190 results for "".
New Analysis of Benzene Contamination in BPO Products
https://practicaldermatology.com/series/dermwire-tv/new-analysis-benzene-contamination-bpo-products/29074/In this week's DermwireTV, new data continues to raise concerns about benzene contamination in BPO products; the FDA expands the approved dosage for Ameluz for actinic keratosis (AK); and in our PA Perspectives segment, Andrew Mastro discusses how to approach a contract negotiation.- Meta-Analysis: Similar AK Clearance With PDT and Cryotherapyhttps://practicaldermatology.com/news/meta-analysis-finds-similar-ak-clearance-with-pdt-and-cryotherapy/2486675/A recent systematic review and meta-analysis suggested comparable efficacy and safety of photodynamic therapy (PDT) and cryotherapy for lesion clearence in actinic keratosis (AK). The analysis, published in the Journal of
- Almirall's Klisyri Gets FDA Approval for AKshttps://practicaldermatology.com/news/almiralls-klisyri-gets-fda-approval-for-aks/2460632/Almirall is expected to launch Klisyri® (tirbanibulin) for the topical treatment of actinic keratosis (AK) of the face or scalp in the first quarter of 2021, after receiving FDA approval this week. Klisyri® is a novel, topic
- Update from DFB Soria on Enrollment in Phase 2 Clinical Trial of Nanoparticle Paclitaxel Ointment for AKhttps://practicaldermatology.com/news/update-from-dfb-soria-on-enrollment-in-phase-2-clinical-trial-of-nanoparticle-paclitaxel-ointment-for-ak/2458039/DFB Soria, a clinical-stage pharmaceutical development company, and an affiliate of NanOlogy™, completed the second of four patient cohorts enrolled in a Phase 2 actinic keratosis (AK) clinical trial of a topical ointment containing nanoparticle
- Pierre Fabre and Hill Dermaceuticals Partner in Commercial Partnership for TOLAK for AKshttps://practicaldermatology.com/news/pierre-fabre-and-hill-dermaceuticals-partner-in-commercial-partnership-for-tolak-for-aks/2458258/Pierre Fabre Dermo-Cosmetique and Hill Dermaceuticals, Inc. have entered into a strategic commercial partnership for TOLAK, a patented prescription dermatologic drug, indicated for the topical treatment of actinic keratosis lesions of the face, ears, and/or scalp. Under the terms of the a
- Galderma Acquires Spirighttps://practicaldermatology.com/news/20121213-galderma_acquires_spirig/2459659/Galderma Pharma S.A. and Spirig Pharma A.G. entered into a definitive agreement under which Galderma will acquire Spirig. Spirig's products treat conditions such as solar damage, skin barrier function impairment, and actinic keratosis. Leading br
- Picato Approved in European Unionhttps://practicaldermatology.com/news/20121119-picato_approved_in_european_union/2459677/The European Commission has granted marketing authorization for LEO Pharma's Picato (ingenol mebutate) gel for the treatment of actinic keratosis in the European Union (EU). Picato was approved in the US earlier this year.
- DUSA Launches “Spot the Signs of AK” Campaignhttps://practicaldermatology.com/news/20120320-dusa_launches_spot_the_signs_of_ak_campaign/2459840/DUSA Pharmaceuticals, Inc. introduced a new campaign called “Spot the Signs of AK” to boost awareness for actinic keratosis. The goal of the campaign is to inform the public about the dangers of cumulative sun damage and how it can cause AKs.
Scientifically Speaking: Optimized Approaches to AK Management
https://practicaldermatology.com/topics/skin-cancer-photoprotection/scientifically-speaking-optimized-approaches-to-ak-management/19912/What's new in AK therapy? From a new, first-in-class molecule to updated approaches with long-standing treatments, the management of actinic keratosis continues to evolve. Scientifically Speaking host Joel L. Cohen, MD speaks with Neal Bhatia, MD, Michael H. Gold, MD, and George Martin, MD about the- Almirall Presents Early-Stage Pipeline Progress for Tirbanibulinhttps://practicaldermatology.com/news/Almirall-Presents-Early-Stage-Pipeline-Progress-Tirbanibulin/2471540/Almirall, S.A. presented five scientific posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, including new data on tirbanibulin, a topical treatment for actinic keratosis (AK), and progress of its early-stage asset LAD191, a high-affinity monoclonal antib